公开(公告)号：US20240424045A1

公开(公告)日：2024-12-26

申请号：US18566653

申请日：2023-01-10

Applicant: OmniActive Health Technologies Limited

Inventor： Muralidhara PADIGARU ,  Abhijeet MORDE ,  Manutosh ACHARYA ,  Sumit PATIL ,  Ninad PURANIK ,  Anup DESHPANDE ,  Munja BAKAN

IPC: A61K36/29 ,  A61K31/015 ,  A61K31/14 ,  A61K31/355 ,  A61K31/4525 ,  A61K45/06 ,  A61P25/28

Abstract: The present invention relates to an oral berberis extract composition and the process for the preparation of the composition of berberis extract as whole or its salts and/or in combination with berberine, jatrorrhizine, and columbamine or its salts with at least one pharmaceutically and/or nutraceutically accepted excipients for prevention, improvement, and maintenance of cognitive health to a subject in need thereof. Further encompassing to the oral berberis composition wherein the berberis extract is comprised of berberis extract as whole or its salts and/or in combination with berberine and/or its salt, and optionally jatrorrhizine, and columbamine or its salts in different forms like powder, beadlets, granules, capsules, tablets, oil suspension, films or any other suitable oral or topical dosage forms. A method of use of the berberis extract composition for prevention, improvement, and maintenance of cognitive health.

公开(公告)号：US20240423998A1

公开(公告)日：2024-12-26

申请号：US18712654

申请日：2022-11-15

Applicant: WOOLSEY PHARMACEUTICALS, INC.

Inventor： Thomas MACALLISTER ,  Sven JACOBSON

IPC: A61K31/551 ,  A61P25/28

Abstract: The invention is based on the discovery that rho kinase inhibitors, particularly fasudil can be used to treat agitation/anxiety in dementia patients, particularly Alzheimer's disease patients. Fasudil treatment of Alzheimer's patients resulted in improvements in agitation that are orders of magnitude to that observed with other potential therapeutic agents.

公开(公告)号：US12173030B2

公开(公告)日：2024-12-24

申请号：US17041835

申请日：2019-03-21

Applicant: AZTHERAPIES, INC.

Inventor： Philip G. Ashton-Rickardt

IPC: A61P25/28 ,  A61K39/00 ,  C07K16/28

Abstract: The invention provides compositions and methods for suppressing autoimmune components of neurodegenerative diseases and thereby providing therapeutic effects to patients suffering from such diseases. Compositions and methods include immunosuppressive moieties such as regulatory T cells (Tregs) and proteins expressed by Tregs coupled to a chimeric antigen receptor or protein that specifically binds one or more glial cell markers. Therapeutically effective doses of said compounds for treating neurodegenerative diseases including progressive supranuclear palsy (PSP), Parkinson's disease (PD), Alzheimer's, Huntington's disease, amyotrophic lateral sclerosis (ALS), chronic traumatic encephalopathy (CTE), and prion diseases are disclosed.

公开(公告)号：US20240417798A1

公开(公告)日：2024-12-19

申请号：US18712387

申请日：2022-11-23

Applicant: Anavex Life Sciences Corp.

Inventor： Christopher U. Missling

IPC: C12Q1/6883 ,  A61K31/341 ,  A61P25/28

Abstract: The present disclosure provides methods for individualized selection of, and monitoring of treatment using a neurodegenerative therapeutic agent such as Sigma-1 receptor agonist therapy for a subject, based on changes in gene expression pre- and post-treatment. The present disclosure also provides methods to evaluate current status or risk of a subject in developing neurodegenerative disorders. Also provided are kits for practicing the methods.

公开(公告)号：US12168657B2

公开(公告)日：2024-12-17

申请号：US17984018

申请日：2022-11-09

Applicant: Ventus Therapeutics U.S., Inc.

Inventor： Stéphane Dorich ,  Amandine Chefson

IPC: C07D471/04 ,  A61P25/28

Abstract: The present disclosure relates to inhibitors of NLRP3 useful in the treatment of diseases and disorders inhibited by said protein.

公开(公告)号：US20240408043A1

公开(公告)日：2024-12-12

申请号：US18262762

申请日：2022-01-27

Applicant: SOCIETE DES PRODUITS NESTLE S.A.

Inventor： FREDERIC RONGA ,  GUILLAUME JACOT ,  TERESA MENDES ,  LOUISE BAUR ,  INDIA C. SEVERIN ,  CARMEN SANDI

IPC: A61K31/198 ,  A61K31/4415 ,  A61K31/714 ,  A61P25/28

Abstract: The present invention relates to compositions comprising N-acetylcysteine and B vitamins for increasing motivational performance and/or mental energy. The present invention further relates to such compositions provided as a kit together with a digital tool such as a companion App.

公开(公告)号：US20240401052A1

公开(公告)日：2024-12-05

申请号：US18807343

申请日：2024-08-16

Applicant: AcuraStem Incorporated

Inventor： Wen-Hsuan CHANG ,  Justin K. ICHIDA

IPC: C12N15/113 ,  A61P25/28

Abstract: The present invention relates to UNC13A cryptic exon antisense oligonucleotides (ASOs), pharmaceutical compositions containing them, and methods for treating, inhibiting, suppressing, and preventing neurological diseases with them.

公开(公告)号：US20240398824A1

公开(公告)日：2024-12-05

申请号：US18741408

申请日：2024-06-12

Applicant: The Johns Hopkins University

Inventor： Seulki Lee ,  Han Seok Ko ,  Ted M. Dawson ,  Martin G. Pomper ,  Donghoon Kim ,  Yumin Oh ,  Seung-Hwan Kwon ,  Yong Joo Park

IPC: A61K31/5377 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/5025 ,  A61K31/504 ,  A61K31/519 ,  A61K31/529 ,  A61P25/28

Abstract: Provided herein are compositions comprising a RIPK2 inhibitor and methods of using the RIPK2 inhibitor for treating or preventing neurodegenerative diseases or disorders. Also provided herein are methods of screening or identifying therapeutic agents useful for treating or preventing neurodegenerative diseases or disorders.

公开(公告)号：US20240398803A1

公开(公告)日：2024-12-05

申请号：US18802247

申请日：2024-08-13

Applicant: University of Kentucky Research Foundation

Inventor： Jayakrishna Ambati ,  Benjamin Fowler ,  Kameshwari Ambati

IPC: A61K31/506 ,  A61P25/16 ,  A61P25/28 ,  C07D411/04

Abstract: The present disclosure relates to compounds, compositions, and methods useful for treating Parkinson's disease. Alzheimer's disease, and multiple sclerosis.

公开(公告)号：US12156896B2

公开(公告)日：2024-12-03

申请号：US18204044

申请日：2023-05-31

Applicant: Lisa Geng

Inventor： Lisa Geng

IPC: A61K36/185 ,  A23L27/10 ,  A23L27/12 ,  A23L33/00 ,  A23L33/105 ,  A23L33/12 ,  A61K31/07 ,  A61K31/197 ,  A61K31/198 ,  A61K31/202 ,  A61K31/205 ,  A61K31/355 ,  A61K31/375 ,  A61K31/4188 ,  A61K31/4415 ,  A61K31/455 ,  A61K31/51 ,  A61K31/519 ,  A61K31/525 ,  A61K31/593 ,  A61K31/714 ,  A61K33/04 ,  A61K33/06 ,  A61K33/24 ,  A61K33/30 ,  A61K33/32 ,  A61K33/34 ,  A61K35/20 ,  A61K36/24 ,  A61K36/27 ,  A61K36/328 ,  A61K36/54 ,  A61K36/81 ,  A61K36/82 ,  A61K36/9066 ,  A61P25/28

Abstract: Nutrient compositions comprising botanical extracts and methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive function and/or one or more aspects thereof, or for treating stroke or seizures and/or ameliorating one or more symptoms thereof are also disclosed.